{
    "Trade/Device Name(s)": [
        "QUANTA Lite\u2122 Celiac DGP Screen",
        "QUANTA Lite\u2122M Celiac DGP Screen"
    ],
    "Submitter Information": "INOVA Diagnostics, Inc.",
    "510(k) Number": "K062708",
    "Predicate Device Reference 510(k) Number(s)": [],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "MST"
    ],
    "Summary Letter Date": "December 13, 2006",
    "Summary Letter Received Date": "September 11, 2006",
    "Submission Date": "September 8, 2006",
    "Regulation Number(s)": [
        "21 CFR 866.5750"
    ],
    "Regulation Name(s)": [
        "Radioallergosorbent (RAST) Immunological Test System"
    ],
    "Analyte Class(es)": [
        "immunology"
    ],
    "Analyte(s)": [
        "IgA antibodies to synthetic, deamidated gliadin-derived peptides",
        "IgG antibodies to synthetic, deamidated gliadin-derived peptides"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Enzyme-linked immunosorbent assay (ELISA)"
    ],
    "Methodologies": [
        "ELISA"
    ],
    "Submission Type(s)": [
        "Assay"
    ],
    "Document Summary": "FDA 510(k) summary for QUANTA Lite\u2122 Celiac DGP Screen ELISA for detection of IgA/IgG antibodies to deamidated gliadin peptides for celiac disease diagnosis",
    "Indications for Use Summary": "Semi-quantitative detection of IgA and IgG antibodies to synthetic, deamidated gliadin-derived peptides in human serum to aid in diagnosing celiac disease and dermatitis herpetiformis",
    "fda_folder": "Immunology"
}